Gene Therapy of Cancer, Third Edition: Translational Approaches from Preclinical Studies to Clinical Implementation

0 valoración promedio
( 0 valoraciones por Goodreads )
 
9780123942951: Gene Therapy of Cancer, Third Edition: Translational Approaches from Preclinical Studies to Clinical Implementation

Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive.

Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies.

In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response.

  • Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches
  • Presents in-depth description of targeting systems and treatment strategies
  • Covers the breadth of gene therapy approaches including immunotherapeutic, drug resistance,oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA

"Sinopsis" puede pertenecer a otra edición de este libro.

About the Author:

Edmund C. Lattime is Professor of Surgery at the Robert Wood Johnson Medical School and Deputy Director, The Cancer Institute of New Jersey. Dr. Lattime studies tumor immunology and immunotherapy focusing on the tumor-host interaction and the tumor microenvironment. While faculty at Sloan Kettering and then Thomas Jefferson University, his translational studies led to the development and Phase I testing of a novel Vaccinia-GMCSF construct designed to enhance the development of antitumor immunity via infection/transfection of the tumor microenvironment. Based on his mechanistic studies of immune escape mechanisms, his group recently developed and is testing a poxvirus-based immunization strategy, which uses antigen encoding poxvirus delivered to the tumor microenvironment, in patients with locally-advanced pancreatic cancer.

Stanton L Gerson is Director of the Case Comprehensive Cancer Center & the National Center for Regenerative Medicine at Case Western Reserve University and Director of University Hospitals Seidman Cancer Center in Cleveland. Dr. Gerson studies DNA repair, stem cells and cancer therapy. He showed that over-expression of the MGMT DNA repair gene could prevent cancer and that a mutant form of MGMT protects hematopoietic stem cells from chemotherapy using lentiviral gene therapy. He has interrogated MGMT, MMR and BER DNA repair pathways as targets for cancer therapy, and proposed that methoxyamine would block base excision repair used in combination with chemotherapy. Dr. Gerson also directed the initial use of mesenchymal stem cells (MSCs) in bone marrow transplantation & in gene therapy.

Review:

"The Third Edition...provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells."--Anticancer Research 34, 2014 "Gene therapy for cancer encompasses reforming genes gone bad, using gene expression to alter the function of both tumor and microenvironment, increasing the sensitivity of cancer cells to killer drugs, and protecting normal cells from such therapies. The studies here cover viral and non-viral vector methodologies: targets and approaches, oncolytic viruses, immunotherapeutics, drug resistance and metabolism gene therapy, cancer therapy imaging vectors, and issues in trail design review and approval."--Reference & Research Book News, December 2013

"Sobre este título" puede pertenecer a otra edición de este libro.

Los mejores resultados en AbeBooks

1.

Lattime, Edmund C.
ISBN 10: 0123942950 ISBN 13: 9780123942951
Nuevos Cantidad: 5
Librería
Paperbackshop-US
(Wood Dale, IL, Estados Unidos de America)
Valoración
[?]

Descripción 2013. HRD. Estado de conservación: New. New Book. Shipped from US within 10 to 14 business days. Established seller since 2000. Nº de ref. de la librería TE-9780123942951

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 137,24
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 3,42
A Estados Unidos de America
Destinos, gastos y plazos de envío

2.

Editorial: Elsevier Science Publishing Co Inc, United States (2013)
ISBN 10: 0123942950 ISBN 13: 9780123942951
Nuevos Tapa dura Cantidad: 10
Librería
The Book Depository US
(London, Reino Unido)
Valoración
[?]

Descripción Elsevier Science Publishing Co Inc, United States, 2013. Hardback. Estado de conservación: New. 3rd Revised edition. Language: English . Brand New Book. Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive. Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies. In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response. Nº de ref. de la librería AA59780123942951

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 140,76
Convertir moneda

Añadir al carrito

Gastos de envío: GRATIS
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

3.

Editorial: Elsevier Science Publishing Co Inc, United States (2013)
ISBN 10: 0123942950 ISBN 13: 9780123942951
Nuevos Tapa dura Cantidad: 10
Librería
The Book Depository
(London, Reino Unido)
Valoración
[?]

Descripción Elsevier Science Publishing Co Inc, United States, 2013. Hardback. Estado de conservación: New. 3rd Revised edition. Language: English . Brand New Book. Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive. Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies. In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response. Nº de ref. de la librería AA59780123942951

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 146,65
Convertir moneda

Añadir al carrito

Gastos de envío: GRATIS
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

4.

Lattime, Edmund C. (Editor)/ Gerson, Stanton L. (Editor)
Editorial: Academic Pr (2013)
ISBN 10: 0123942950 ISBN 13: 9780123942951
Nuevos Tapa dura Cantidad: 2
Librería
Revaluation Books
(Exeter, Reino Unido)
Valoración
[?]

Descripción Academic Pr, 2013. Hardcover. Estado de conservación: Brand New. 3rd edition. 537 pages. 10.75x8.75x1.25 inches. In Stock. Nº de ref. de la librería __0123942950

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 143,51
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 6,69
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

5.

LATTIME, EDMUND; GERSON, STANTON
Editorial: Academic Press (2013)
ISBN 10: 0123942950 ISBN 13: 9780123942951
Nuevos Tapa dura Cantidad: 10
Librería
Herb Tandree Philosophy Books
(Stroud, GLOS, Reino Unido)
Valoración
[?]

Descripción Academic Press, 2013. Hardback. Estado de conservación: NEW. 9780123942951 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. Nº de ref. de la librería HTANDREE0893453

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 157,80
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 8,91
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

6.

LATTIME, EDMUND; GERSON, STANTON
Editorial: Academic Press (2013)
ISBN 10: 0123942950 ISBN 13: 9780123942951
Nuevos Tapa dura Cantidad: 10
Librería
Herb Tandree Philosophy Books
(Stroud, GLOS, Reino Unido)
Valoración
[?]

Descripción Academic Press, 2013. Hardback. Estado de conservación: NEW. 9780123942951 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. Nº de ref. de la librería HTANDREE01197368

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 157,80
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 8,91
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

7.

Editorial: Elsevier Science Publishing Co Inc, United States (2013)
ISBN 10: 0123942950 ISBN 13: 9780123942951
Nuevos Tapa dura Cantidad: 1
Librería
Book Depository hard to find
(London, Reino Unido)
Valoración
[?]

Descripción Elsevier Science Publishing Co Inc, United States, 2013. Hardback. Estado de conservación: New. 3rd Revised edition. Language: English . This book usually ship within 10-15 business days and we will endeavor to dispatch orders quicker than this where possible. Brand New Book. Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive. Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies. In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response. Nº de ref. de la librería BTE9780123942951

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 174,05
Convertir moneda

Añadir al carrito

Gastos de envío: GRATIS
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

8.

Editorial: Academic Press (2013)
ISBN 10: 0123942950 ISBN 13: 9780123942951
Nuevos Tapa dura Cantidad: 1
Librería
Irish Booksellers
(Rumford, ME, Estados Unidos de America)
Valoración
[?]

Descripción Academic Press, 2013. Hardcover. Estado de conservación: New. book. Nº de ref. de la librería 0123942950

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 178,46
Convertir moneda

Añadir al carrito

Gastos de envío: GRATIS
A Estados Unidos de America
Destinos, gastos y plazos de envío

9.

Edmund Lattime
ISBN 10: 0123942950 ISBN 13: 9780123942951
Nuevos Tapa dura Cantidad: 1
Librería
AussieBookSeller
(SILVERWATER, NSW, Australia)
Valoración
[?]

Descripción 2013. Hardcover. Estado de conservación: New. 3rd. Hardcover. Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from th.Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. 554 pages. 1.837. Nº de ref. de la librería 9780123942951

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 203,16
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 31,73
De Australia a Estados Unidos de America
Destinos, gastos y plazos de envío